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APP5 peptide and P165 could promote the proliferation of cultured hippocam-
pal neural stem cells derived from rat embryo, increase the amount of precur-
sor cells of hippocampal dentate gyrus in adult rat brain. However, these two
peptides could not affect the differationation of the above precursor cells in
vivo or in vitro. The mechanism is probably related with the PI3’K transduc-
tion pathway.
P2-448 PRECLINICAL EVALUATION OF CDD-0102, A
SELECTIVE M1 AGONIST WITH POTENTIAL
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Carol Green3, Debasis Ghosh2, Wayne Hoss1,2, Edward J. McGuire2,
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Background: Agonists that selectively activate M1 muscarinic receptors
might be useful in treating memory and cognitive deficits, while preventing the
formation of amyloid plaques and neurofibrillary tangles associated with Alz-
heimer’s disease. 5-(3-Ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimi-
dine trifluoroacetic acid (CDD-0102J) displays functional selectivity for M1
receptors and enhances memory function in animals with cholinergic deficits.
The hydrochloride salt (CDD-0102A) also promotes alpha-secretase activity
and reverses the apoptotic effects of Abeta in differentiated PC12 cells.
Methods: CDD-0102A was evaluated in a series of studies to determine
pharmacokinetic parameters, drug metabolism and toxicity. Results: Preclin-
ical toxicology studies indicate that CDD-0102A is negative in bacterial
mutagenicity, mammalian cell clastogenicity, and mouse micronucleus assays.
Moreover, CDD-0102A does not inhibit the HEK-hERG channel current. In a
28-day repeat-dose toxicity study with CDD-0102A in male and female rats,
excessive cholinergic stimulation was apparent at high doses yet no overt
toxicities were observed. Dogs were more sensitive to CDD-0102A in a
comparable study with dose-dependent increased frequency and severity of
cholinergic symptoms, although no significant effects on cardiovascular and
pulmonary safety parameters were observed. Studies in rats yielded linear
pharmacokinetics with dose proportional increases in Cmax and AUC and an
estimated t1/2 of 3-5 hr. Comparative drug metabolism studies indicated sig-
nificant metabolism only in rabbit S9 preparations, with limited metabolism in
liver microsomal and S9 preparations from mice, rats, dogs, monkeys and
humans. Three potential metabolites were identified from rabbit liver micro-
somes. Conclusions: The preclinical data are being used in planning Phase I
clinical studies of CDD-0102A in healthy adult volunteers. Taken together, the
data suggest that CDD-0102A may be useful in treating the symptoms and
some of the underlying causes of Alzheimer’s disease.
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Background: NMDA receptor-mediated excitotoxicity is thought to underlie
a variety of neurological disorders. It has recently been shown that calpain
activation is involved in NMDA receptor-related excitotoxicity cascades. The
aim of the present study was to examine the neuroprotective effects of the
novel calpain inhibitor A-705253 (water-soluble, low molecular weight com-
pound; Ki  27 nM) in hippocampal slice cultures and in vivo, using excito-
toxic lesions of the nucleus basalis magnocellularis (NBM) in rat. Me hods:
For analysis of in vitro neurodegeneration we used the model of NMDA-
induced spectrin cleavage in hippocampal slice cultures. Various concentra-
tions of A-705253 were applied before NMDA application, and spectrin
degradation products were assessed by Western blot analysis. In vivo neuro-
protective effects were investigated by measuring functional and morpholog-
ical deficiencies induced by NMDA-induced lesions of cholinergic neurons in
the nucleus basalis magnocellularis (NBM). NMDA was injected unilaterally
into the NBM one hour after application of either A-705253 or the respective
vehicles. Behavioral effects were recorded 4-6 days after the insult followed by
measurement of the density of cholinergic fibers in the parietal cortex and
microglial reaction at the lesion site. Results: Application of A-705253 sig-
nificantly prevented NMDA-induced spectrin degradation in slice cultures
with an IC50 of 100 nM. In vivo, NMDA lesions markedly decreased perfor-
mance in novel object recognition experiments. The NMDA-lesioned group
treated with MK-801 performed at levels comparable to those of the sham-
lesioned control. Treatment with A-705253 dose-dependently prevented the
deficit. A-705253 (10 mg/kg) completely prevented the effect of the lesion
(p0.005). Open field activity was virtually not affected by either lesion or
treatment, indicating that lesions did not produce unspecific behavioral effects.
Subsequent analysis of choline acetyltransferase in cortex revealed that appli-
cation of A-705253 dose-dependently prevented neurodegeneration of cholin-
ergic fibers (p0.01 for 3 and 10 mg/kg). The 10 mg/kg dose also significantly
prevented the accompanying gliosis, as determined by immunohistochemical
analysis of microglial activation. Conclusions: We conclude that inhibition of
calpain represents a valuable strategy for the prevention of excitotoxicity-
induced neurodegeneration and may thus be a novel approach for the treatment
of a variety of neurodegenerative disorders.
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Background: Cerebrolysin is a peptide preparation acting like endogenous
neurotrophic factors and has been shown to decrease amyloid burden by
regulating APP maturation and transport. Since neurodegenerative alterations
in AD might also be related to changes in neurogenesis, these studies aimed to
investigate the ability of Cerebrolysin to stimulate neurogenesis in the hip-
pocampus. Methods: Transgenic mThy1-hAPP751 (n24), non-transgenic
(n12) mice and wildtype Wistar rats (n24) were loaded with BrdU and
treated with Cerebrolysin for up to 3 months. Markers for new born cells
(BrdU), proliferation (PCNA), migrating neuroblasts (DCX), neuronal pheno-
type (NeuN) and apoptosis (TUNEL) were analysed in the granular/subgranu-
lar layers of the hippocampus. Results: The vehicle-treated APP tg mice
showed decreased numbers of BrdU and DCX neural stem cells in the
dentate gyrus compared to non-tg controls. APP tg mice treated with Cere-
brolysin resulted in a significant increase of BrdU cells, DCX neuroblasts
and a decrease in TUNEL neural stem cells compared to vehicle treated APP
tg mice. Cerebrolysin did neither change the number of PCNA proliferating
neural stem cells nor the ratio of BrdU cells converting to neurons and
astroglia. A significant increase in the number of BrdU positive neurons was
also observed in rat hippocampi. Interestingly, these neurons were found more
frequently as pairs in Cerebrolysin treated rats than in controls suggesting that
Cerebrolysin rescues one of the daughter cells. Furthermore, this increase in
number of neurons correlated with improved cognitive performance. Conclu-
sions: These findings have shown that Cerebrolysin promotes neurogenesis by
protecting neuronal stem cells and decreasing the rate of apoptosis. Together
with a reduction of amyloid production, neurogenic effects of Cerebrolysin
might contribute to the alleviation of the synaptic and cognitive deficits in
patients with AD.
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